|
KMID : 0545120180280060849
|
|
Journal of Microbiology and Biotechnology
2018 Volume.28 No. 6 p.849 ~ p.859
|
|
|
Antiviral Effect of Retro-2.1 against Herpes Simplex Virus Type 2 In Vitro
|
|
Dai Wenwen
Wu Yu
Bi Jinpeng
Wang Jingyu
Wang Shuai
Kong Wei
Barbier Julien
Cintrat Jean-Christophe
Gao Feng
Jiang Zhengran
Gillet Daniel
Su Weiheng
Jiang Chunlai
|
|
|
Abstract
|
|
|
|
Herpes simplex virus type 2 (HSV-2) infection has been a public health concern worldwide. It is the leading cause of genital herpes and a contributing factor to cervical cancer and human immunodeficiency virus (HIV) infection. No vaccine is available yet for the treatment of HSV- 2 infection, and routinely used synthetic nucleoside analogs have led to the emergence of drug resistance. The small molecule Retro-2cycl has been reported to be active against several pathogens by acting on intracellular vesicle transport, which also participates in the HSV-2 lifecycle. Here, we showed that Retro-2.1, which is an optimized, more potent derivative of Retro-2cycl, could inhibit HSV-2 infection, with 50% inhibitory concentrations of 5.58 μM and 6.35 μM in cytopathic effect inhibition and plaque reduction assays, respectively. The cytotoxicity of Retro-2.1 was relatively low, with a 50% cytotoxicity concentration of 116.5 μM. We also preliminarily identified that Retro-2.1 exerted the antiviral effect against HSV-2 by a dual mechanism of action on virus entry and late stages of infection. Therefore, our study for the first time demonstrated Retro-2.1 as an effective antiviral agent against HSV-2 in vitro with targets distinct from those of nucleoside analogs.
|
|
|
KEYWORD
|
|
|
Herpes simplex virus type 2, Retro-2.1, antiviral effect, entry, late stage, vesicle transport
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|